Anti-PD-L1 inhibitor durvalumab in bladder cancer

Lancet Oncol. 2016 Jul;17(7):e275. doi: 10.1016/S1470-2045(16)30242-X. Epub 2016 Jun 16.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • B7-H1 Antigen / genetics
  • Humans
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • durvalumab